There are 2789 resources available
1429P - Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
Presenter: Salah-Eddin Al-Batran
Session: ePoster Display
1430P - Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
Presenter: Christina Kopp
Session: ePoster Display
1431P - Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital
Presenter: Oriol Mirallas
Session: ePoster Display
1432P - Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced gastric cancer patients
Presenter: Manuel Cabeza-Segura
Session: ePoster Display
1243P - Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status
Presenter: Evan Strom
Session: ePoster Display
1244P - Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)
Presenter: Mircea Dediu
Session: ePoster Display
1245P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
Presenter: Ruifen Tian
Session: ePoster Display
1246P - A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Presenter: Toyoaki Hida
Session: ePoster Display
1247P - Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Presenter: Keunchil Park
Session: ePoster Display
1248P - Osimertinib and crizotinib cardiotoxicity: Are real-world studies the way forward?
Presenter: Hasan Kobat
Session: ePoster Display